Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 2 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Ratio — FY 2024 | Parmaneti | GNG Pharma | Iberi + | Akhali Khedva | Iberiparma + |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 18.2% | 35.8% | — | — | — |
| EBITDA Margin | 5.7% | 4.1% | — | — | — |
| EBITDAR | 436 | 709 | — | — | — |
| EBITDAR Margin | 6.5% | 11.3% | — | — | — |
| EBIT Margin | 5.2% | 3.4% | — | — | — |
| Net Profit Margin | 3.8% | 0.5% | — | — | — |
| Operating Expense % of Sales | 12.5% | 31.7% | — | — | — |
| Returns | |||||
| Return on Assets (ROA) | 11.0% | 2.1% | — | — | — |
| Return on Equity (ROE) | 23.1% | 5.1% | — | — | — |
| ROIC [EBIT / Invested Capital] | 19.1% | 50.1% | — | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 34.0% | 0.0% | — | — | — |
| Debt-to-Equity | 0.71x | 0.00x | — | — | — |
| Debt-to-EBITDA | 2.03x | 0.00x | — | — | — |
| Equity-to-Assets | 47.7% | 40.1% | — | — | — |
| Net Debt | 732 | -127 | — | — | — |
| Cash & Equivalents | 49 | 127 | — | — | — |
| Total Debt | 781 | N/A | — | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.68x | 1.52x | — | — | — |
| Quick Ratio | 1.68x | 1.52x | — | — | — |
| Cash Ratio | 0.08x | 0.16x | — | — | — |
| Total Current Assets | 1,061 | 1,243 | — | — | — |
| Total Current Liabilities | 632 | 819 | — | — | — |
| Inventory | N/A | N/A | — | — | — |
| Trade Receivables | 204 | 55 | — | — | — |
| Trade Payables | 382 | 804 | — | — | — |
| Net Working Capital | 429 | 424 | — | — | — |
| Net Working Capital % of Revenue | 6.4% | 6.8% | — | — | — |
| Trade Working Capital | -178 | -749 | — | — | — |
| Trade Working Capital % of Revenue | -2.7% | -12.0% | — | — | — |
| Change in Trade Working Capital | N/A | N/A | — | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | — | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | — | — | — |
| Receivables Turnover | 32.77x | 114.53x | — | — | — |
| Days Sales Outstanding (DSO) | 11.1 | 3.2 | — | — | — |
| Payables Turnover | 14.33x | 4.99x | — | — | — |
| Days Payable Outstanding (DPO) | 25.5 | 73.1 | — | — | — |
| Cash Conversion Cycle | -14.3 days | -70.0 days | — | — | — |
| Asset Turnover | 2.91x | 4.57x | — | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 250 | 73 | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | 173 | 73 | — | — | — |
| Cash Conversion (OCF / EBITDA) | 65.0% | 28.5% | — | — | — |
| Dividends Declared | N/A | N/A | — | — | — |
| Dividend Payout Ratio | N/A | N/A | — | — | — |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Parmaneti | Pharma | 5.7% | 25th pct | 110 |
| GNG Pharma | Pharma | 4.1% | 20th pct | 110 |
| Iberi + | Pharma | — | no FY data | 110 |
| Akhali Khedva | Pharma | — | no FY data | 110 |
| Iberiparma + | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.